361 related articles for article (PubMed ID: 25189201)
1. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
3. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
[TBL] [Abstract][Full Text] [Related]
7. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
11. [Gynecologic cancer].
Sugiyama T; Takeuchi S; Fukagawa T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):157-61. PubMed ID: 24743194
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab treatment of prostate cancer.
Small AC; Oh WK
Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
17. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
18. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]